Ser122

Site Information
RKRNRHCssHQsRsK SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 34367913
Available spectra: 1 CST

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 )
Disease tissue studied:	brain cancer ( 2 ) , glioblastoma ( 2 ) , glioma ( 2 ) , lung cancer ( 1 ) , small-cell lung cancer ( 1 )
Relevant cell line - cell type - tissue:	DMS79 (pulmonary) ( 1 ) , lung ( 1 ) , M059K (glial) ( 2 ) , NCI-H128 (pulmonary) ( 1 ) , NCI-H1417 (pulmonary) ( 1 ) , NCI-H209 (pulmonary) ( 1 ) , NCI-H524 (pulmonary) ( 1 )

References
1	Rikova K, Hall B (2013) CST Curation Set: 20734, 21161, 30112, 30153, 30154; Year: 2013; Biosample/Treatment: cell line, H1417, DMS79, H128, H209, H524; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
2	Stokes M (2007) CST Curation Set: 2262; Year: 2007; Biosample/Treatment: cell line, M059K/UV; Disease: glioblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) ATM/ATR Substrate Antibody Cat#: 2851 Curated Info